CD19 and B-cell chronic lymphocytic leukemia: The TRANSCEND-CLL-004 study evaluated lisocabtagene maraleucel (liso-cel), a CD19-directed autologous CAR T-cell product, in patients with CLL who had received at least two prior lines of therapy including a BTKi [15].